Identification of a novel series of selective 5-HT7 receptor antagonists

Bioorganic and Medicinal Chemistry Letters

Volumn 13, Issue 6, 2003, Pages 1055-1058

  Forbes, Ian T ^a   Cooper, David G ^a   Dodds, Emma K ^a   Douglas, Sara E ^a   Gribble, Andrew D ^a   Ife, Robert J ^a   Lightfoot, Andrew P ^a   Meeson, Malcolm ^a   Campbell, Lorraine P ^a   Coleman, Tanya ^a   Riley, Graham J ^a   Thomas, David R ^a  

^a GLAXOSMITHKLINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

FUSED ALICYCLIC AROMATIC COMPOUND; SB 691673; SEROTONIN 7 RECEPTOR; SEROTONIN ANTAGONIST; UNCLASSIFIED DRUG;

ARTICLE; DRUG IDENTIFICATION; DRUG POTENCY; DRUG SCREENING; DRUG SELECTIVITY; MOLECULAR MODEL; STRUCTURE ACTIVITY RELATION;

CYTOCHROME P-450 ENZYME SYSTEM; DRUG DESIGN; DRUG EVALUATION, PRECLINICAL; HUMANS; INDICATORS AND REAGENTS; ISOENZYMES; MODELS, MOLECULAR; RECEPTORS, SEROTONIN; SEROTONIN ANTAGONISTS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0037463760     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0960-894X(03)00077-5     Document Type: Article

References (15)

1. For a recent review of serotonin receptors, see: Hoyer D., Hannon J.P., Martin G.R. Pharmacol. Biochem. Behav. 71:2002;533.
2. (a) Bard J.A., Zgombick J., Adham N., Vaysee P., Branchek T.A., Weinshank R.L. J. Biol. Chem. 268:1993;23422
3. (b) Ruat M., Traiffort E., Leurs R., Tardivel-Lacombe J., Diaz J., Arrang J.-M., Schwarz J. C. Proc. Natl. Acad. Sci. U.S.A. 90:1993;8547
4. (c) To Z.P., Bonhaus D.W., Eglen R.M., Jakeman L.B. Br. J. Pharm. 115:1995;107
5. (d) Shen Y., Monsma F.J., Metcalf M.A., Jose P.A., Hamblin M.W., Sibley D.R. J. Biol. Chem. 268:1993;18200.
6. Lovenberg T.W., Baron B.M., deLecea L., Miller J.O., Prosser R.A., Rea M.A., Foye P.E., Rucke M., Slone A.L., Siegel B.W., Danielson P.E., Sutcliffe J.G., Erlander M.G. Neuron. 11:1993;449.
7. Guscott, M. Poster Presentation, Society for Neurosciences Satellite Meeting on Serotonin, New Orleans, November, 2000.
8. (a) Lovell P.J., Bromidge S.M., Dabbs S., Duckworth D.M., Forbes I.T., Jennings A.J., King F.D., Middlemiss D.N., Rahman S.K., Saunders D.V., Collin L.L., Hagan J.J., Riley G.J., Thomas D.R. J. Med. Chem. 43:2000;342
9. (b) Forbes, I. T.; Douglas, S.; Gribble, A. D.; Ife, R. J.; Lightfoot, A. P.; Garner, A. E.; Riley, G. J.; Jeffrey, P.; Stevens A. J.; Stean, T. O.; Thomas, D. R. Bioorg. Med. Chem Lett. 2002, 12, 3341.
10. Unpublished work in GSK.
11. Chiral HPLC separation of the individual enantiomers from two members of this series indicated rapid racemisation of the chiral centre, following isolation of the samples from each peak.
12. i values represent the mean of at least three determinations using cell lines stably expressing the cloned human receptor. For details of the radioligand binding assays, see refs 5 and 9.
13. Hagan J.J., Price G.W., Jeffrey P., Deeks N.J., Stean T., Piper D., Smith M.I., Upton N., Medhurst A.D., Middlemiss D.N., Riley G.J., Lovell P.J., Bromidge S.M., Thomas D.R. Br. J. Pharm. 130:2000;539.
14. The profile of SB-691673 is consistent with an inverse agonist as the basal response of adenyly cyclase was reduced in the absence of agonist (5-CT).
15. Cytochrome P450 enzyme activities were determined by quantifying the production of fluorescent metabolite following incubation of substrate with heterologously expressed cytochrome P450 enzymes obtained from the Gentest Corporation. A generic description of this approach can be found in: Anal. Biochem. 1997, 248, 188, or at www.gentest.com.